NO20014103L - N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens - Google Patents

N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens

Info

Publication number
NO20014103L
NO20014103L NO20014103A NO20014103A NO20014103L NO 20014103 L NO20014103 L NO 20014103L NO 20014103 A NO20014103 A NO 20014103A NO 20014103 A NO20014103 A NO 20014103A NO 20014103 L NO20014103 L NO 20014103L
Authority
NO
Norway
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
NO20014103A
Other languages
English (en)
Other versions
NO20014103D0 (no
NO319793B1 (no
Inventor
Maria Kuerthy
Katalin Biro
Karoly Nagy
Laszlo Ueroegdi
Zita Csakai
Jenoe Szilbereky
Tamas Mogyorosi
Magdolna Toeroek
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Zoltan Nagy
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of NO20014103D0 publication Critical patent/NO20014103D0/no
Publication of NO20014103L publication Critical patent/NO20014103L/no
Publication of NO319793B1 publication Critical patent/NO319793B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014103A 1999-02-26 2001-08-23 N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3-karboksimidoylklorid og dets anvendelse til fremstilling av et farmasoytisk preparat, samt farmasoytisk preparat. NO319793B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (3)

Publication Number Publication Date
NO20014103D0 NO20014103D0 (no) 2001-08-23
NO20014103L true NO20014103L (no) 2001-10-22
NO319793B1 NO319793B1 (no) 2005-09-12

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014103A NO319793B1 (no) 1999-02-26 2001-08-23 N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3-karboksimidoylklorid og dets anvendelse til fremstilling av et farmasoytisk preparat, samt farmasoytisk preparat.

Country Status (27)

Country Link
US (1) US6649628B1 (no)
EP (1) EP1163224B1 (no)
JP (1) JP4689838B2 (no)
KR (1) KR100676124B1 (no)
AT (1) ATE237590T1 (no)
AU (1) AU779096B2 (no)
BG (1) BG65178B1 (no)
BR (1) BR0008969A (no)
CA (1) CA2360451C (no)
CZ (1) CZ297386B6 (no)
DE (1) DE60002187T2 (no)
DK (1) DK1163224T3 (no)
EE (1) EE04961B1 (no)
ES (1) ES2193055T3 (no)
HR (1) HRP20010584B1 (no)
HU (1) HUP9900475D0 (no)
IL (2) IL144866A0 (no)
NO (1) NO319793B1 (no)
PL (1) PL197692B1 (no)
PT (1) PT1163224E (no)
RS (1) RS50083B (no)
RU (1) RU2250901C2 (no)
SI (1) SI1163224T1 (no)
SK (1) SK287063B6 (no)
UA (1) UA72495C2 (no)
WO (1) WO2000050403A1 (no)
ZA (1) ZA200106488B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
CA2471752A1 (en) 2002-01-11 2003-07-17 Biorex Kutato Es Fejlesztoe Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
KR20110084514A (ko) * 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
ES2912524T3 (es) 2012-09-14 2022-05-26 Saint Gobain Cristal con un elemento de conexión eléctrica
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
SI3448382T1 (sl) 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
JP2020520947A (ja) 2017-05-24 2020-07-16 オーファザイム エー／エス 熱ショックタンパク質誘導因子および前頭側頭障害
US20210164997A1 (en) 2018-05-28 2021-06-03 Orphazyme A/S Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
WO2021260120A1 (en) 2020-06-24 2021-12-30 Orphazyme A/S Arimoclomol for treating gaucher disease
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
WO2022106614A1 (en) * 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
JP2024502304A (ja) 2020-12-24 2024-01-18 ゼブラ デンマーク エー／エス Ｅｒ型ミスセンス変異を有する患者におけるニーマンピック病ｃ型の治療用アリモクロモル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
SK11582001A3 (sk) 2001-12-03
AU3182400A (en) 2000-09-14
DE60002187T2 (de) 2003-12-11
EE200100447A (et) 2002-12-16
IL144866A (en) 2007-07-04
ZA200106488B (en) 2002-08-07
WO2000050403A1 (en) 2000-08-31
IL144866A0 (en) 2002-06-30
CA2360451C (en) 2011-01-04
PL350915A1 (en) 2003-02-10
SK287063B6 (sk) 2009-10-07
ES2193055T3 (es) 2003-11-01
NO20014103D0 (no) 2001-08-23
US6649628B1 (en) 2003-11-18
CZ20013053A3 (cs) 2002-01-16
AU779096B2 (en) 2005-01-06
PT1163224E (pt) 2003-07-31
RS50083B (sr) 2009-01-22
PL197692B1 (pl) 2008-04-30
BR0008969A (pt) 2001-11-27
DE60002187D1 (de) 2003-05-22
UA72495C2 (uk) 2005-03-15
KR100676124B1 (ko) 2007-01-31
BG105837A (en) 2002-03-29
ATE237590T1 (de) 2003-05-15
HUP9900475D0 (en) 1999-04-28
NO319793B1 (no) 2005-09-12
EP1163224A1 (en) 2001-12-19
DK1163224T3 (da) 2003-08-04
JP4689838B2 (ja) 2011-05-25
HRP20010584A2 (en) 2002-08-31
HRP20010584B1 (en) 2010-08-31
RU2250901C2 (ru) 2005-04-27
CA2360451A1 (en) 2000-08-31
SI1163224T1 (en) 2003-08-31
CZ297386B6 (cs) 2006-11-15
EE04961B1 (et) 2008-02-15
YU60301A (sh) 2004-05-12
JP2002537384A (ja) 2002-11-05
KR20010102410A (ko) 2001-11-15
EP1163224B1 (en) 2003-04-16
BG65178B1 (bg) 2007-05-31

Similar Documents

Publication Publication Date Title
NO20014103D0 (no) N-[2-hydroksy-3 (1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens
GB0223038D0 (en) Therapeutic compounds
EA200101166A1 (ru) Ингибиторы металлопротеаз
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
TW229205B (no)
NO20061736L (no) Krystallform av epotilon B
MY106315A (en) Pharmaceutical agents
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
AP2000001934A0 (en) Antipicornaviral compounds, their preparation and use.
ATE320811T1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE69531098D1 (de) Piperidine und pyrrolidine
YU85303A (sh) Upotreba enantiomerno čistog escitaloprama
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
NO20024291L (no) Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
DK1232173T3 (da) Nye fusidinsyrederivater
IL165996A0 (en) Novel thiophene acyl hydrazino derivatives method for preparing same use thereof as medicines pharmaceutical compositions and novel use
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees